Vimta Labs Reports Q2 FY26 Revenue of Rs. 1,045 Mn, Up 22.3% YoY
Filing Summary
Vimta Labs Limited announced its unaudited financial results for Q2 and H1 FY26, reporting a record quarterly revenue of Rs. 1,045 million, marking a 22.3% increase year-over-year. The company’s EBITDA margin stood at 35.3%, while the PAT margin was 19.1%. For the half-year period, total income reached Rs. 2,038 million, a 26.6% rise from the previous year. The company completed the sale of its Diagnostic and Pathological services to Thyrocare Technologies in October 2024. These results reflect Vimta Labs’ continued focus on its core research and testing services.
Vimta Labs Limited has released its unaudited financial results for the second quarter and half-year ending September 30, 2025. The company reported its highest-ever quarterly revenue of Rs. 1,045 million, representing a 22.3% increase compared to the same quarter in the previous fiscal year. The results were disclosed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
For Q2 FY26, Vimta Labs reported a total income of Rs. 1,045 million, up from Rs. 854 million in Q2 FY25. The EBITDA, including other income, was Rs. 369 million, reflecting a 20.6% increase year-over-year. The EBITDA margin for the quarter was 35.3%. The Profit After Tax (PAT) from continued operations was Rs. 199 million, with a PAT margin of 19.1%. The Basic Earnings Per Share (EPS) for the quarter was Rs. 4.5. For the half-year period, total income was Rs. 2,038 million, a 26.6% increase from Rs. 1,610 million in H1 FY25. The EBITDA for H1 FY26 was Rs. 723 million, with a margin of 35.5%, and PAT was Rs. 388 million, with a PAT margin of 19.0%.
The operational focus of Vimta Labs remains on its core services, including pharmaceutical research and testing, and food testing services. The company has regrouped previous period figures to ensure comparability with the current period, following the sale of its Diagnostic and Pathological services business to Thyrocare Technologies. This transaction was announced on August 30, 2024, and completed on October 11, 2024.
The results reflect Vimta Labs’ strategic emphasis on maintaining high standards in its research and testing services. The company successfully underwent a WHO audit for Clinical Research during the quarter, underscoring its commitment to global quality and compliance standards. The focus remains on enhancing capabilities and delivering value through its scientific and technical expertise.
The timeline of significant events includes the completion of the sale of the Diagnostic and Pathological services business in October 2024. This strategic move allows Vimta Labs to concentrate on its core competencies in contract research and testing services.
**About Vimta Labs Limited:** Founded in 1984, Vimta Labs Limited is a leading contract research and testing organization based in Hyderabad, India. The company provides integrated scientific, technical, and regulatory expertise to support product development and manufacturing processes across various sectors, including food, pharmaceuticals, medical devices, and environmental assessments. Vimta Labs is committed to maintaining excellence in quality, innovation, and competence.